Cellulitis and Erysipelas

• Bacterial adherence and invasion: Streptococcus pyogenes (Group A Streptococcus, GAS) and Staphylococcus aureus express surface proteins including M protein, hyaluronic acid capsule, and lipoteichoic acids that facilitate adhesion to host epithelial cells and extracellular matrix components. M protein mimics human cardiac myosin and other host antigens, enabling molecular mimicry and evasion of complement-mediated killing. Breaches in the skin barrier (abrasions, insect bites, surgical wounds, tinea pedis) allow bacterial access to dermal and subcutaneous layers. Once established, bacteria produce hyaluronidase and streptokinase enzymes that degrade connective tissue barriers and facilitate rapid spread through tissue planes.

• Virulence factor-mediated tissue destruction: Streptococcal pyrogenic exotoxins (SPEs—particularly SPE A, B, and C) function as superantigens, bypassing normal T-cell receptor recognition to directly cross-link MHC class II molecules on antigen-presenting cells with T-cell receptors. This causes massive, nonspecific T-cell activation (up to 20% of T-cells versus <0.01% in conventional antigen presentation), resulting in explosive cytokine release including TNF-α, IL-1, IL-6, and IFN-γ. Staphylococcal α-toxin (α-hemolysin) creates pores in cell membranes, leading to cell lysis and inflammatory cell recruitment. Panton-Valentine leukocidin (PVL), produced by some methicillin-resistant S. aureus (MRSA) strains, similarly destroys white blood cells, reducing local immune defenses.

• Lymphatic involvement and clinical localization: In cellulitis, infection predominantly spreads through tissue planes with less organized lymphatic involvement, producing poorly demarcated borders as inflammation extends centrifugally. In contrast, erysipelas preferentially involves dermal and superficial lymphatic channels, triggering lymphangitis and regional lymphadenopathy. The raised, sharply demarcated borders of erysipelas result from organized lymphatic obstruction creating a wall of inflammation. This anatomic difference explains why erysipelas commonly affects the face (rich superficial lymphatic network) while cellulitis more frequently involves the lower extremities.

• Innate immune response and complement activation: TLR-mediated recognition of streptococcal and staphylococcal pathogen-associated molecular patterns (PAMPs) activates MyD88-dependent signaling cascades in dendritic cells and resident tissue macrophages, upregulating pro-inflammatory cytokines. Complement activation occurs via both classical (antibody-mediated) and alternative pathways; GAS produces streptococcal pyrogenic exotoxin M (SpM) and other factors that inhibit complement factor C3 deposition, reducing opsonization. Neutrophil recruitment through CXCL8/IL-8 gradients represents the dominant early innate response; however, PVL and α-toxin cause neutrophil lysis, paradoxically amplifying inflammation.

• Edema formation and vascular permeability: Inflammatory mediators including histamine, bradykinin, leukotrienes (LTC4, LTD4, LTE4), and prostaglandins (PGE2, PGI2) increase endothelial permeability through VE-cadherin disruption and tight junction protein phosphorylation. VEGF (vascular endothelial growth factor) released by macrophages and endothelial cells further increases vascular permeability and promotes neovascularization. This results in exudative edema, warmth from increased local blood flow, and the characteristic erythema from vasodilation.

Primary Bacterial Pathogens

• **Group A Streptococcus (Streptococcus pyogenes)**: The most common pathogen in both cellulitis (60-70% of cases) and erysipelas (90%+ of cases). GAS produces multiple virulence factors including M protein, hyaluronic acid capsule, streptolysins, and streptococcal pyrogenic exotoxins. Produces sharply demarcated, raised borders characteristic of erysipelas and can cause rapidly progressive, necrotizing soft tissue infections. Universally susceptible to penicillin and cephalosporins.

• Staphylococcus aureus (including MRSA): Increasingly common as a cellulitis pathogen (20-30% of cases), particularly in healthcare-associated settings and in patients with recent antibiotics, hospitalization, or indwelling devices. Methicillin-resistant strains now account for approximately 50-60% of community-onset S. aureus cellulitis in many regions. Produces Panton-Valentine leukocidin (PVL), α-toxin, and toxic shock syndrome toxin-1 (TSST-1), enabling more aggressive tissue invasion and abscess formation. Notably, MRSA cellulitis may be associated with purulent collections (abscesses) requiring drainage.

Predisposing Conditions and Risk Factors

• Disrupted skin barrier: Tinea pedis (dermatophyte infection with inflammatory response) is the most common predisposing condition for lower extremity cellulitis, present in 70-80% of leg cellulitis cases. Other causes include surgical wounds, trauma, burns, insect bites, injection drug use sites, intravenous lines, and ulcers (diabetic, venous, pressure-related). Chronic dermatitis and lichenification impair barrier function.

• Lymphedema and venous insufficiency: Account for 70-80% of recurrent cellulitis cases. Lymphedema reduces local immune defenses through impaired lymphatic clearance and T-cell trafficking; venous insufficiency causes skin edema, impaired oxygen delivery, and reduced antimicrobial peptide production. Unilateral presentation in the context of prior lymph node dissection or unilateral varicose veins should raise suspicion.

• Diabetes mellitus: Associated with 25-30% of cellulitis cases. Hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and killing; reduces antimicrobial peptide expression; and promotes advanced glycation end products (AGEs) that impair wound healing. Diabetic patients have higher complication rates and longer hospital stays.

• Immunosuppression: HIV/AIDS (particularly CD4 <200 cells/μL), transplant recipients, chronic corticosteroid use, TNF-α inhibitors, and other immunosuppressive agents increase susceptibility and severity. Recurrent cellulitis may be the presenting sign of underlying immunodeficiency.

• Obesity and metabolic syndrome: Increased adipose tissue produces pro-inflammatory cytokines and reduced antimicrobial peptides; obesity impairs lymphatic drainage and increases skin-to-skin friction.

• Age extremes: Infants and elderly patients have relatively impaired immune responses. Erysipelas shows a bimodal distribution with peaks in infants (<5 years) and elderly (>60 years).

• Recurrent cellulitis: Defined as ≥3 episodes within 3 years in the same location. Risk factors include uncontrolled tinea pedis, inadequately treated lymphedema, chronic venous insufficiency, and obesity. Prophylactic antibiotics (typically benzathine penicillin G 1.2 million units IM monthly) are indicated.

Systemic Symptoms

• Fever and chills: Occur in 30-50% of cellulitis cases and up to 90% of erysipelas cases. Fever typically develops acutely over 24-48 hours and reflects the superantigen-driven cytokine release. High fevers (≥39°C) with rigors should prompt concern for bacteremia and systemic inflammatory response syndrome (SIRS), particularly in immunocompromised patients.

• Malaise and constitutional symptoms: Fatigue, body aches, and headache reflect IL-1, TNF-α, and IL-6-mediated systemic effects. More prominent in erysipelas and bacteremic presentations.

Local Cutaneous Manifestations

• Erythema: The hallmark finding, typically appears as bright red or pink discoloration. In cellulitis, borders are poorly demarcated and blend gradually into surrounding skin; in erysipelas, borders are sharply demarcated, raised, and well-defined ("orange peel" texture). Erythema results from vasodilation mediated by prostaglandins and histamine released by mast cells in response to bacterial superantigens and inflammatory cytokines.

• Edema and induration: Soft tissue swelling with pitting edema in cellulitis (due to increased vascular permeability and inflammatory exudate) versus nonpitting, brawny edema in erysipelas (due to organized lymphatic obstruction). Induration indicates dermal/subcutaneous inflammation with collagen deposition.

• Warmth: Increased local temperature results from increased blood flow and metabolic activity of inflammatory cells. Typically confined to the affected area, though systemic temperature elevation indicates systemic response.

• Lymphangitis and lymphadenopathy: Red streaking along lymphatic vessels with tender regional lymph node enlargement occurs in both conditions but is more prominent in erysipelas. Lymphatic inflammation reflects lymphatic invasion by bacteria and local immune activation.

Classic Location-Specific Presentations

• Facial erysipelas: Classically involves the cheeks, nose, and forehead with "butterfly" distribution. Sharp demarcation with raised borders is most apparent on face due to rich superficial lymphatic network. Often includes associated conjunctivitis or rhinitis.

• Lower extremity cellulitis: Most common site, often with unilateral presentation. Frequently bilateral in lymphedema. Commonly associated with tinea pedis between toes and with hyperpigmentation/hemosiderin deposition from chronic venous insufficiency. Cellulitis extending above the knee warrants concern for deeper soft tissue involvement.

• Upper extremity cellulitis: Often follows lymph node dissection for breast cancer or occurs in chronic lymphedema states. May present with remarkable swelling with minimal erythema in pure lymphedema settings.

Important Clinical Variants

• Purulent cellulitis with abscess formation: Increasingly common with MRSA, presenting with fluctuant collections requiring drainage. Absence of purulence does not exclude MRSA—most MRSA cellulitis remains nonpurulent. Presence of purulence should prompt empiric MRSA coverage and consideration of incision and drainage (I&D).

• Cellulitis with systemic toxicity: Rapid progression with severe constitutional symptoms, hypotension, altered mental status, and high fever (often >40°C) may indicate streptococcal toxic shock syndrome (STSS) or early necrotizing fasciitis. STSS occurs when toxin-producing GAS strains trigger massive T-cell activation and cytokine storm. Associated mortality is 20-50% even with appropriate treatment.

• Periorbitial and periocular cellulitis: Cellulitis involving the eyelids and periocular tissues (without posterior orbital involvement) presents with lid edema, chemosis, and sometimes proptosis. Risk of cavernous sinus thrombosis if untreated; requires prompt IV antibiotics and imaging to exclude orbital abscess.

• Cellulitis with lymphangitis and systemic manifestations: Presence of lymphangitic red streaking with high fever and marked systemic toxicity indicates higher inoculum and more aggressive infection, warranting hospitalization even if otherwise immunocompetent.

Clinical Diagnosis (Primary Approach)

• Cellulitis criteria: Acute onset (typically within 48 hours of barrier disruption or prodrome) of unilateral erythema with poorly demarcated borders, edema, warmth, and regional lymphadenopathy. Often painful or tender. May have preceding skin break or known risk factor (diabetes, lymphedema, tinea pedis).

• Erysipelas criteria: Sharply demarcated, raised, bright red plaques with "orange peel" texture. Classically involves face, ears, or lower extremities. More prominent systemic symptoms with high fever. Rapidly advancing borders. Rarely includes purulent collections.

Distinguishing Features

Laboratory Testing (Limited Role, But Helpful in Specific Contexts)

• Blood cultures: Positive in only 5% of uncomplicated cellulitis and up to 15% of erysipelas; not routinely recommended for outpatient management of mild-to-moderate cellulitis. Indicated in: (1) systemic toxicity/fever ≥39°C, (2) immunocompromised patients, (3) rapidly progressive disease, (4) consideration of hospitalization, (5) facial cellulitis or periorbital involvement (higher bacteremia risk).

• Complete blood count (CBC): Typically shows leukocytosis (WBC 12,000-20,000/μL) with left shift; higher WBC counts (>30,000/μL) suggest more severe infection or possible necrotizing soft tissue infection. Normal WBC does not exclude infection, particularly in elderly or immunocompromised patients. Absolute lymphopenia or thrombocytopenia may portend worse prognosis.

• Inflammatory markers: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are nonspecific but may be markedly elevated (CRP often >10 mg/dL, ESR >50 mm/h). Useful for baseline comparison if monitoring response to therapy in complex cases, though not required for diagnosis. Rapidly falling CRP suggests appropriate treatment response.

• Skin culture: Not routinely indicated for uncomplicated cellulitis (yield <5%) unless: (1) bullae present (may identify causative organism, especially important for V. vulnificus or A. hydrophila if associated with seawater exposure), (2) purulent drainage or abscess present (send for culture and sensitivities; may guide antibiotic selection for MRSA), (3) immunocompromised host, (4) failure to respond to standard therapy.

• Streptococcal serology: Not useful for acute diagnosis. Anti-streptolysin O (ASO) and anti-DNase B titers rise 7-14 days after infection but do not influence acute management.

Imaging (Selective Use)

• Ultrasound: Increasingly used as first-line imaging. Can identify subcutaneous edema (hypoechoic infiltration), presence of fluid collections/abscess (anechoic or complex fluid with septations), and lymphangitis (dilated hypoechoic lymphatic channels). Useful for determining depth of

Immediate assessment (first decision point)

• Exclude necrotizing infection before committing to medical therapy: pain out of proportion, rapid progression over hours, crepitus, bullae, skin anesthesia, or hypotension mandates urgent surgical consultation. Per the IDSA 2014 skin and soft tissue infection (SSTI) guideline, surgical exploration is both diagnostic and therapeutic — imaging must never delay it.
• Sepsis physiology: IV fluids, blood cultures, and broad-spectrum IV antibiotics within the first hour, consistent with Surviving Sepsis Campaign practice.

First-line therapy — nonpurulent cellulitis/erysipelas (streptococcal)

• Beta-lactams: IDSA recommends antistreptococcal coverage alone. Mild outpatient disease: oral penicillin V, amoxicillin, or a first-generation cephalosporin (cephalexin). Moderate/severe or systemically ill: IV cefazolin or penicillin G.
• Duration: 5 days for uncomplicated infection per IDSA, extended only if improvement is incomplete.
• Penicillin allergy: cephalosporins are acceptable for non-anaphylactic histories — true cross-reactivity is roughly 1–3% and driven by shared R1 side chains, not the beta-lactam ring. For anaphylaxis, use clindamycin or a glycopeptide.

Purulent cellulitis/abscess

• Incision and drainage is the definitive treatment; antibiotics are adjunctive. Add MRSA coverage: oral trimethoprim-sulfamethoxazole, doxycycline, or clindamycin; IV vancomycin, linezolid, or daptomycin for severe disease. Vancomycin is dosed to a 24-hour AUC targeting AUC/MIC 400–600 (2020 IDSA/ASHP consensus), not a 15–20 mcg/mL trough.

Escalation and adjuncts

• Streptococcal toxic shock: add clindamycin for ribosomal suppression of exotoxin synthesis (Eagle effect — penicillin is less effective against stationary-phase organisms).
• Supportive care: limb elevation to reduce edema, and treatment of the portal of entry, especially tinea pedis with a topical azole or allylamine.
• Recurrence prophylaxis: IDSA supports suppressive penicillin (including IM benzathine penicillin G) after ≥3 episodes per year once predisposing factors are addressed.

Avoid

• Routine MRSA coverage for nonpurulent cellulitis — not supported by IDSA.
• Topical antibiotics as monotherapy, and corticosteroids in undifferentiated disease.
• Doxycycline/TMP-SMX in pregnancy (fetal effects; TMP-SMX is antifolate and avoided near term).

Emergencies — recognize immediately

• Necrotizing fasciitis: bacterial spread along fascial planes with thrombosis of perforating vessels causes tissue ischemia. Signalled by pain out of proportion to exam, rapid progression, crepitus, hemorrhagic bullae, dusky skin, and cutaneous anesthesia (destruction of dermal nerves). Emergent surgical debridement plus broad-spectrum antibiotics; IDSA emphasizes that imaging must not delay exploration.
• Streptococcal toxic shock syndrome: superantigen-driven cytokine storm producing hypotension, multiorgan failure, and desquamation. Emergency; add clindamycin for toxin suppression.
• Bacteremia and sepsis: hematogenous seeding from dermal lymphatics; suspect with rigors, hypotension, or persistent high fever. Higher yield of blood cultures in erysipelas and immunocompromised hosts.
• Orbital cellulitis and cavernous sinus thrombosis: retrograde spread through valveless facial/ophthalmic veins from periorbital or midface infection. Red flags are proptosis, painful or restricted extraocular movement, diplopia, and cranial nerve III/IV/VI palsies. Emergent CT orbits and IV antibiotics.

Local and delayed complications

• Abscess formation: liquefactive necrosis walled off by fibrin; fluctuance or a hypoechoic collection on point-of-care ultrasound. Requires drainage.
• Osteomyelitis and septic arthritis: contiguous extension, classically over the tibia or in diabetic foot ulcers; suspect with probe-to-bone, persistent drainage, or failure to defervesce.
• Post-streptococcal glomerulonephritis: immune-complex deposition after GAS skin infection — cola-colored urine, edema, hypertension, low C3. Antibiotics do not prevent it. Acute rheumatic fever does not follow skin infection.
• Lymphedema and recurrence: each episode scars lymphatics, impairing clearance and predisposing to the next — a self-perpetuating cycle.

Treatment-related

• Clindamycin: Clostridioides difficile colitis — new watery diarrhea on therapy.
• Vancomycin: acute kidney injury (especially with piperacillin-tazobactam) and infusion-rate–related flushing from histamine release.
• TMP-SMX: hyperkalemia (ENaC blockade), rising creatinine from tubular secretion blockade, and severe cutaneous reactions.
• Linezolid: reversible myelosuppression and serotonin syndrome with SSRIs (MAO inhibition).

• **Sharply demarcated, raised, indurated border with peau d'orange texture on the face** is erysipelas until proven otherwise, and the organism is Streptococcus pyogenes. Poorly demarcated, flat, gradually blending erythema on the leg is cellulitis.
• The single best next step for pain out of proportion, crepitus, or hemorrhagic bullae is surgical consultation for exploration, not CT, not MRI, not broader antibiotics. IDSA is explicit that imaging must not delay debridement.
• Nonpurulent versus purulent drives antibiotic choice: nonpurulent → antistreptococcal beta-lactam (cephalexin/cefazolin) with no MRSA coverage; purulent → incision and drainage plus MRSA coverage (TMP-SMX, doxycycline, clindamycin). Adding vancomycin to simple nonpurulent cellulitis is the classic over-treatment distractor.
• Always look between the toes: tinea pedis is the most common portal of entry for lower-extremity cellulitis, and failing to treat it is the most tested reason for recurrence.
• Erythema may transiently expand in the first 24–48 hours after starting antibiotics as bacterial lysis releases inflammatory mediators. This is not treatment failure — do not switch agents if fever and pain are improving.
• The association examiners love: GAS skin infection can be followed by post-streptococcal glomerulonephritis (cola-colored urine, low C3) but not acute rheumatic fever. Antibiotics prevent rheumatic fever after pharyngitis, not glomerulonephritis after pyoderma.
• Bilateral lower-extremity "cellulitis" is almost always pseudocellulitis — stasis dermatitis, lipodermatosclerosis, or contact dermatitis. Cellulitis is nearly always unilateral, painful, and febrile; stasis dermatitis is itchy, chronic, and hemosiderin-stained.
• Exposure clues: saltwater plus cirrhosis and hemorrhagic bullae → Vibrio vulnificus (doxycycline plus a third-generation cephalosporin); freshwater → Aeromonas hydrophila; cat or dog bite → Pasteurella multocida (amoxicillin-clavulanate).